WebSep 6, 2024 · Camptothecin, a cytotoxic drug, is a strong inhibitor of nucleic acid synthesis in mammalian cells and a potent inducer of strand breaks in chromosomal DNA. WebApr 30, 2024 · HER2 targeted therapies have significantly improved prognosis of HER2-positive breast and gastric cancer. HER2 overexpression and mutation is the pathogenic driver in non-small cell lung cancer (NSCLC) and colorectal cancer, however, to date, there are no approved HER2-targeted therapies with these indications. Trastuzumab …
Phase I and Pharmacokinetic Study of DX-8951f (Exatecan …
WebSep 3, 2002 · A lower level of resistance was observed against DX-8951f and 10,11-methylenedioxy-20(S)-camptothecin, respectively 9.0- and 9.3-fold, while the activity of both camptothecin and BNP1350 was not ... http://wukongzhiku.com/hangyechanye/112640.html small instamatic camera
Trastuzumab deruxtecan (Enhertu) - HemOnc.org
WebJan 1, 2003 · Abstract. We determined the antitumor and antimetastatic efficacy of the camptothecin analogue DX-8951f in an orthotopic metastatic mouse model of pancreatic cancer. DX-8951f showed efficacy against two human pancreatic tumor cell lines in this model. These cell lines were transduced with the green fluorescent protein, enabling high … WebNov 29, 2024 · Background Camptothecin (CPT) and its derivatives are currently used as second- or third-line treatment for patients with endocrine-resistant breast cancer (BC). These drugs convert nuclear enzyme DNA topoisomerase I (TOP1) to a cell poison with the potential to damage DNA by increasing the half-life of TOP1-DNA cleavage complexes … WebJun 1, 2024 · e24206 Background: DS-1062a is a trophoblast cell surface protein 2 (TROP2)-targeting antibody-drug conjugate (ADC) comprised of a humanized anti-TROP2 monoclonal antibody, enzymatically cleavable peptide-linker, and a novel topoisomerase I inhibitor DXd which is a derivative of Exatecan (DX-8951). TROP2 is a 36-kDa single … high will services